CRISPR Therapeutics AG
NASDAQ:CRSP
CRISPR Therapeutics AG
NASDAQ:CRSP
Price:
51.47 USD
-3.88%
Updated:
May 10, 2024
CRISPR Therapeutics AG
Cash from Financing Activities
|
CRISPR Therapeutics AG
Cash from Financing Activities Peer Comparison
Comparables:
ADCT
ACIU
BSLN
IDIA
KURN
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Cash from Financing Activities
$62.7m
|
CAGR 3-Years
-60%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Cash from Financing Activities
$73.9m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
AC Immune SA
NASDAQ:ACIU
|
Cash from Financing Activities
CHf43.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Cash from Financing Activities
-CHf57.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-57%
|
CAGR 10-Years
-20%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Cash from Financing Activities
CHf162.3m
|
CAGR 3-Years
396%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Cash from Financing Activities
-CHf171k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is CRISPR Therapeutics AG's Cash from Financing Activities?
Cash from Financing Activities
62.7m
USD
62.7m
USD
Based on the financial report for Dec 31, 2023, CRISPR Therapeutics AG's Cash from Financing Activities amounts to 62.7m USD.
What is CRISPR Therapeutics AG's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-28%
-28%
Over the last year, the Cash from Financing Activities growth was 62%. The average annual Cash from Financing Activities growth rates for CRISPR Therapeutics AG have been -60% over the past three years , -28% over the past five years .
You don't have any saved screeners yet
